-
| Sector | Other |
|---|---|
| Industry | Other |
| CurrencyCode | USD |
| Exchange | NASDAQ |
| ISIN | None |
| Market Cap | None |
|---|---|
| PE Ratio | None |
| Target Price | 4.88 |
| Beta | nan |
| Dividend Yield | None |
BIND Therapeutics, Inc. is a clinical-stage nanomedicine platform company developing Accurins, its targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Its drug candidate, BIND-014, is in Phase II clinical trials for non-small cell lung cancer, or NSCLC, and metastatic castrate-resistant prostate cancer (mCRPC).
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BIND using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025